Iranian Red Crescent Medical Journal

Published by: Kowsar

Frequency of Cholelithiasis in Patients With Beta-Thalassemia Intermedia With and Without Hydroxyurea

Maryam Khavari 1 , Azin Hamidi 2 , Sezaneh Haghpanah 2 , Mohammad Hadi Bagheri 3 , Marzieh Bardestani 4 , Razieh Hantooshzadeh 5 and Mehran Karimi 2 , *
Authors Information
1 Department of Biology, Faculty of Sciences, Zabol University of Medical Sciences, Zabol, IR Iran
2 Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Department of Library and Information Sciences, College of Humanities, Khouzestan Science and Research Branch, Islamic Azad University, Ahvaz, IR Iran
5 Ministry of Health and Medical Education, Tehran, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: July 5, 2014, 16 (7); e18712
  • Published Online: July 5, 2014
  • Article Type: Research Article
  • Received: March 4, 2014
  • Revised: May 7, 2014
  • Accepted: June 11, 2014
  • DOI: 10.5812/ircmj.18712

To Cite: Khavari M, Hamidi A, Haghpanah S, Hadi Bagheri M, Bardestani M, et al. Frequency of Cholelithiasis in Patients With Beta-Thalassemia Intermedia With and Without Hydroxyurea, Iran Red Crescent Med J. 2014 ; 16(7):e18712. doi: 10.5812/ircmj.18712.

Abstract
Copyright © 2014, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Abolghasemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, et al. Thalassemia in Iran: epidemiology, prevention, and management. J Pediatr Hematol Oncol. 2007; 29(4): 233-8[DOI][PubMed]
  • 2. Kliegman R, Stanton B, Behrman R, Schor N. Nelson textbook of pediatrics.
  • 3. Karimi M, Haghpanah S, Farhadi A, Yavarian M. Genotype-phenotype relationship of patients with beta-thalassemia taking hydroxyurea: a 13-year experience in Iran. Int J Hematol. 2012; 95(1): 51-6[DOI][PubMed]
  • 4. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006; 37(1): 12-20[DOI][PubMed]
  • 5. Mishra AK, Tiwari A. Iron overload in Beta thalassaemia major and intermedia patients. Maedica (Buchar). 2013; 8(4): 328-32[PubMed]
  • 6. Karami H, Vahidshahi K, Kosarian M, Karami H, Jamali M. Relationship between Use of Hydroxyurea and Cholelithiasis in Patients with Major and Intermediate β-thalassemia. J Mazandaran Univ Med Sci. 2007; 17(61): 62-8
  • 7. Kosaryan M, Karami H, Zafari M, Yaghobi N. Report on patients with non transfusion-dependent beta-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. Hemoglobin. 2014; 38(2): 115-8[DOI][PubMed]
  • 8. Musallam KM, Taher AT, Rachmilewitz EA. beta-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med. 2012; 2(7)[DOI][PubMed]
  • 9. Taher A, Sheikh-Taha M. Hydroxyurea use in Lebanese patients with beta-thalassemia intermedia. J Pediatr Hematol Oncol. 2006; 28(2): 107[DOI][PubMed]
  • 10. Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol. 2007; 138(3): 291-304[DOI][PubMed]
  • 11. Kattamis A. Treatment of thalassemia with hydroxyurea: an indispensable alternative therapy. J Pediatr Hematol Oncol. 2007; 29(11): 729-30[DOI][PubMed]
  • 12. Patel S, Purohit P, Mashon RS, Dehury S, Meher S, Sahoo S, et al. The effect of hydroxyurea on compound heterozygotes for sickle cell-hemoglobin D-Punjab-A single centre experience in eastern India. Pediatr Blood Cancer. 2014; 61(8): 1341-6[DOI][PubMed]
  • 13. Silva DG, Belini Junior E, Carrocini GC, Torres Lde S, Ricci Junior O, Lobo CL, et al. Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia. BMC Med Genet. 2013; 14: 108[DOI][PubMed]
  • 14. Ehsani MA, Hedayati-Asl AA, Bagheri A, Zeinali S, Rashidi A. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature. Pediatr Hematol Oncol. 2009; 26(8): 560-5[DOI][PubMed]
  • 15. Italia KY, Jijina FJ, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, et al. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India. Clin Chim Acta. 2009; 407(1-2): 10-5[DOI][PubMed]
  • 16. Koren A, Levin C, Dgany O, Kransnov T, Elhasid R, Zalman L, et al. Response to hydroxyurea therapy in beta-thalassemia. Am J Hematol. 2008; 83(5): 366-70[DOI][PubMed]
  • 17. Karimi M, Cohan N, Mousavizadeh K, Falahi MJ, Haghpanah S. Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10 years' experience. Pediatr Hematol Oncol. 2010; 27(3): 205-11[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments